Ignite Creation Date:
2024-05-06 @ 4:15 PM
Last Modification Date:
2024-10-26 @ 2:06 PM
Study NCT ID:
NCT04921345
Status:
RECRUITING
Last Update Posted:
2023-04-07
First Post:
2021-06-04
Brief Title:
Pharmacokinetics Safety and Efficacy of Nemolizumab in Participants With Moderate-to-Severe Atopic Dermatitis
Sponsor:
Galderma RD
Organization:
Galderma RD
Study Overview
Official Title:
A Multicenter Open-Label Single-Group Clinical Trial to Assess the Pharmacokinetics Safety and Efficacy of Nemolizumab CD14152 in Pediatric Subjects Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis
Status:
RECRUITING
Status Verified Date:
2023-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to assess the pharmacokinetics PK efficacy and safety of nemolizumab in pediatric participants with moderate-to-severe atopic dermatitis AD
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None